Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Irinotecan

  • Floris Aart de Jong
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_3148-2

Synonyms

Definition

An intravenously administered classical anticancer drug, registered for the first- and second-line treatment of colorectal cancer. Other administration routes, e.g., oral formulations, have been studied as well.

Characteristics

Colorectal cancer (colon cancer) includes cancer of the colon and the rectum. To give an impression of its burden of disease, in Europe, about 375,000 new cases of colorectal cancer are diagnosed yearly, whereas its incidence in the USA is estimated to be about 150,000 new cases per year, with a small overrepresentation of males (odds ratio, 1.1). Yearly, in Europe, about 200,000 people die from colorectal cancer, making it the second most common cause of cancer death (aging). Over the last years, the death rate from colorectal cancer has gone down somewhat, which is in part attributed to a declining incidence. In addition, as a result of the emerging (systematic) use of screening tests in combination with higher...

Keywords

Hemorrhagic Cystitis Complementary Alternative Medicine Gene UGT1A1 Camptotheca Acuminata Irinotecan Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Benson AB III, Ajani JA, Catalano RB et al (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22:2918–2926CrossRefPubMedGoogle Scholar
  2. de Jong FA, de Jong MJ, Verweij J et al (2006) Role of pharmacogenetics in irinotecan therapy. Cancer Lett 1:90–106CrossRefGoogle Scholar
  3. Fuchs C, Mitchell EP, Hoff PM (2006) Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev 32:491–503CrossRefPubMedGoogle Scholar
  4. Mathijssen RH, Alphen RJ, van Verweij J et al (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182–2194PubMedGoogle Scholar
  5. O’Dwyer PJ (2006) Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 28:4534–4538CrossRefGoogle Scholar

See Also

  1. (2012) Bilirubin. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 401. doi:10.1007/978-3-642-16483-5_6336Google Scholar
  2. (2012) BSA. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 574. doi:10.1007/978-3-642-16483-5_746Google Scholar
  3. (2012) Camptothecin. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 603. doi:10.1007/978-3-642-16483-5_791Google Scholar
  4. (2012) Carboxylesterase. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 641. doi:10.1007/978-3-642-16483-5_834Google Scholar
  5. (2012) Cleavable Complex. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 880. doi:10.1007/978-3-642-16483-5_1212Google Scholar
  6. (2012) Crigler-Najjar Syndrome. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 994. doi:10.1007/978-3-642-16483-5_6335Google Scholar
  7. (2012) Enterohepatic Recirculation. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1259. doi:10.1007/978-3-642-16483-5_1912Google Scholar
  8. (2012) 5-Fluorouracil. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1429. doi:10.1007/978-3-642-16483-5_2223Google Scholar
  9. (2012) Gilbert Syndrome. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1545. doi:10.1007/978-3-642-16483-5_2407Google Scholar
  10. (2012) β-Glucuronidase. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1558. doi:10.1007/978-3-642-16483-5_2432Google Scholar
  11. (2012) Glucuronidation. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1558. doi:10.1007/978-3-642-16483-5_2433Google Scholar
  12. (2012) Jaundice. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1926. doi:10.1007/978-3-642-16483-5_3174Google Scholar
  13. (2012) Pharmacodynamics. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2840. doi:10.1007/978-3-642-16483-5_4495Google Scholar
  14. (2012) Pharmacogenetics. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2840. doi:10.1007/978-3-642-16483-5_4496Google Scholar
  15. (2012) Pharmacokinetics. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2845. doi:10.1007/978-3-642-16483-5_4500Google Scholar
  16. (2012) Prodrug. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2989. doi:10.1007/978-3-642-16483-5_4751Google Scholar
  17. (2012) SN-38. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3456. doi:10.1007/978-3-642-16483-5_5386Google Scholar
  18. (2012) St. John’s Wort. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3499. doi:10.1007/978-3-642-16483-5_5477Google Scholar
  19. (2012) UGT1A1. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 3835–3836. doi:10.1007/978-3-642-16483-5_6334Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Amgen BVBredaThe Netherlands